See more : GeoJunxion N.V. (GOJXN.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Arcutis Biotherapeutics, Inc. (ARQT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcutis Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Australian Mines Limited (AMSLF) Income Statement Analysis – Financial Results
- BrainChip Holdings Ltd (BRN.AX) Income Statement Analysis – Financial Results
- Hazoor Multi Projects Limited (HAZOOR.BO) Income Statement Analysis – Financial Results
- Braime Group PLC (BMTO.L) Income Statement Analysis – Financial Results
- HCI Group, Inc. (HCI) Income Statement Analysis – Financial Results
Arcutis Biotherapeutics, Inc. (ARQT)
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.99M | 754.00K | 763.00K | 455.00K | 195.00K | 0.00 | 0.00 |
| Gross Profit | 54.62M | 2.93M | -763.00K | -455.00K | -195.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 91.63% | 79.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M | 3.41M |
| General & Administrative | 0.00 | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Other Expenses | 0.00 | 5.82M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Operating Expenses | 295.72M | 304.56M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Cost & Expenses | 300.71M | 305.31M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Interest Income | 0.00 | 9.83M | 173.00K | 967.00K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 29.71M | 15.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 1.25M | 763.00K | 455.00K | 195.00K | 19.74M | 4.11M |
| EBITDA | -227.43M | -294.55M | -205.59M | -135.22M | -41.80M | 480.00K | -872.00K |
| EBITDA Ratio | -381.56% | -8,025.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.74M | -4.11M |
| Operating Income Ratio | -404.49% | -8,183.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -17.93M | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Income Before Tax | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Income Before Tax Ratio | -434.57% | -8,449.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.11M | 9.83M | -454.00K | -84.30K | 23.14K | -480.00K | -4.11M |
| Net Income | -262.14M | -321.29M | -205.90M | -135.68M | -42.00M | -19.26M | -4.98M |
| Net Income Ratio | -439.79% | -8,716.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| EPS Diluted | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| Weighted Avg Shares Out | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
| Weighted Avg Shares Out (Dil) | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Morgan Stanley 22nd Annual Global Healthcare...
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & CEO Todd Edwards - Chief Commercial Officer Patrick...
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), please note that in the section of Recent Corporate Highlights, in the third bullet point,...
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.16 per share a year ago.
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,000 restricted stock units of Arcutis' common...
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practices Provides access to a large portion of the 7.4 million individuals treated for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis outside of dermatology offices ZORYVE will...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be used anywhere on the body for any duration to maintain clear skin Atopic...
7 Biotech Stocks to Keep on Your Clinical Radar
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions...
Source: https://incomestatements.info
Category: Stock Reports